Clinical trial
Study of HIV-1 Rgp-160 Administered by Mucosal Routes in Healthy Volunteers
NCT00122564 · French National Agency for Research on AIDS and Viral Hepatitis, Other · Terminated
Key facts
| NCT number | NCT00122564 |
|---|---|
| Title | Study of HIV-1 Rgp-160 Administered by Mucosal Routes in Healthy Volunteers |
| Official title | Phase I Study Evaluating the Systemic and Mucosal Safety and Immunogenicity of a Recombinant HIV-1 Gp 160 (MN/LAI) Administered by Transmucosal (Nasal or Vaginal) Routes, Alone or Formulated With DC-Chol, in HIV Negative Volunteers (ANRS VAC14) |
| Lead sponsor | French National Agency for Research on AIDS and Viral Hepatitis, Other |
| Collaborators | Aventis Pharmaceuticals Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Biological |
| Interventions | HIV-1 gp 160, DC-Chol |
| Enrollment | 36 |
| Start date | Jun 1, 2003 |
| Completion | Apr 1, 2005 |
| First posted | Jul 22, 2005 |
| Last update posted | Nov 11, 2005 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: